The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020
Why the study?
New data and experience since 2010, including advances in percutaneous interventions, risk stratification, and medical treatments, necessitated updated guidelines for adult congenital heart disease management.
Key Points
- Standardized clinical recommendations improve decision-making in adult congenital heart disease, refining timing for catheter intervention and medical therapies across adult lifespans.
- Guideline consensus integrates clinical trial data since 2010 into revised care standards, detailing pulmonary arterial hypertension protocols alongside active arrhythmia management.
- Highlights the essential role of adult congenital heart disease expert centers, broadening surveillance protocols for thoracic aortic disease, coronary anomalies, and complex pregnancies.
Structured PICO
P
Population
Adult patients with congenital heart disease (ACHD)
E
Exposure
Clinical practice guidelines for management, including diagnosis, timing of intervention, risk assessment, and medical treatment
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“One of the key messages of this document is... that [congenital heart disease] is a lifelong disease. We are in the happy situation that [most of our patients with congenital heart disease now survive into adulthood], but most of them are not cured and require lifelong follow-up in order to recognize any complications timely and deal with them adequately.”
“Having a congenital heart disease, with a need for long-term follow-up and treatment, can also have an impact on social life, limit employment options and make it difficult to get insurance. Guiding and supporting patients in all of these processes is an inherent part of their care.”
“Pre-conception counselling is recommended for women and men to discuss the risk of the defect in offspring and the option of foetal screening.”
Implication
The 2020 ESC guidelines update the 2010 version with new concepts in disease complexity, catheter interventions, and specific medical treatments for adult congenital heart disease.
Abstract
Since the previous version of the guidelines on the management of grown-up congenital heart disease was published in 2010, new data and experience have accumulated, particularly on percutaneous interventional techniques and on risk stratification with regard to timing of surgery and catheter intervention. Medical treatment options have also emerged for selected indications. This made a revision of the recommendations necessary. Since adult patients with congenital heart disease (CHD) now present in increasing numbers at advanced ages, including the elderly, the term ‘grown-up congenital heart disease’ no longer appeared appropriate and was therefore—in accordance with international literature—replaced with adult congenital heart disease (ACHD) throughout the document. The document focuses on decision-making in ACHD which involves accurate diagnosis, the timing of intervention, risk assessment, and selection of the most suitable type of intervention. In addition, specific aspects of medical treatment such as for heart failure, pulmonary hypertension, and anticoagulation are addressed. Compared to the 2010 version new concepts in the present guidelines include a disease complexity classification, staffing requirements for ACHD expert centres, the emerging role of biomarkers in the follow-up of ACHD, detailed and specific recommendations on arrhythmia management, more specific and adjusted recommendations for pulmonary arterial hypertension (PAH) treatment, recommendations for the use of anticoagulants, consideration of aging and advance care planning, categories of high-risk pregnancies, expansion of the Marfan Syndrome section to inheritable thoracic aortic disease, Turner’s Syndrome and bicuspid aortic disease, and the emerging role of catheter intervention in ACHD. In addition, there is now also a section on coronary anomalies.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Baumgartner et al. (2020) conducted a review in Adult Congenital Heart Disease (ACHD). Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020 was evaluated. The 2020 ESC Guidelines for Adult Congenital Heart Disease provide updated recommendations on diagnosis, timing of intervention, risk assessment, and specific medical treatments for ACHD patients.